Laboratory and clinical studies on TMS-19-Q

Munetaka Komori; Hlroko Nakazato; Masao Nagasawa; Hlronobu Koga; Koichi Watanabe; Yoshiaki Fukuda; Hiroshi Tomita; Naomi Ito; Katsuhiko Sawatari; Yoshiteru Shigeno; Yoji Suzuyama; Kinichi Izumikawa; Atsushi Saito; Kohei Hara; Kazuyuki Sugawara; Chikako Mochida; Mitsuo Kaku; Keizo Yamaguchi; Hiromaru Iwasaki; Tsuneo Tsutsumi; Akira Ikebe; Masamoto Nakano; Kazuhiro Okuno; Rokushi Oka; Tsunetoshi Koteda; Takashi Ishizaki; Toshiyuki Oye; Masao Sai; Haruji Ohmagari

doi:10.11250/chemotherapy1953.32.Supplement6_346

Laboratory and clinical studies on TMS-19-Q

Munetaka Komori, Hlroko Nakazato, Masao Nagasawa, Hlronobu Koga, Koichi Watanabe, Yoshiaki Fukuda, Hiroshi Tomita, Naomi Ito, Katsuhiko Sawatari, Yoshiteru Shigeno, Yoji Suzuyama, Kinichi Izumikawa, Atsushi Saito, Kohei Hara, Kazuyuki Sugawara, Chikako Mochida, Mitsuo Kaku, Keizo Yamaguchi, Hiromaru Iwasaki, Tsuneo TsutsumiAkira Ikebe, Masamoto Nakano, Kazuhiro Okuno, Rokushi Oka, Tsunetoshi Koteda, Takashi Ishizaki, Toshiyuki Oye, Masao Sai, Haruji Ohmagari

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Laboratory and clinical studies on TMS-19-Q, a new macrolide antibiotic, were carried out and the results were as follows 1) Antimicrobial activity The minimal inhibitory concentrations (MICs) of TMS-19-Q against 50 clinical isolates of Mycoplasma pneumoniae (M. pneumoniae) ranged from 0.0035 to 0. 06 μg/ml. The peak MIC of TMS-19-Q was 0. 015 μg/ml, which was superior to those of josamycin (JM) and oleandomycin (OL). The growth inhibitory effect of TMS-19-Q against M. pneumoniae in test tube revealed bactericidal activity in the concentration of 0.5 and 1.0 μg/ml. In the treatment of hamster experimentally infected with M. pneumoniae the viable organisms in the lungs decreased to 102cells/ml on the 3rd day. On the 10 th day of drug treatment, 80% (8 out of 10) of the hamsters receiving TMS-19-Q showed no viable M. pneumoniae cells upon the culture of their lungs. The antimicrobial activity of TMS-19-Q against 50 strains of Legionella pneumophila was almost same as that of erythromycin (EM). The MICs of TMS-19-Q against 155 clinical isolates (Streptococcus pneumoniae 47, Streptococcus pyogenes 54, Streptococcus faecalis 27 and Staphylococcus epidermidis 27) were compared with those of JM and EM. The antibacterial activity of TMS-19-Q was superior to that of JM and was almost equal to that of EM. 2) Absorption and excretion in humans The average peak plasma level of TMS-19-Q in six healthy adult volunteers after single oral dosage of 600 mg with TMS-19-Q·O tablet was 0. 5 μg/ml; while same dosage of TMS-19-Q with GC tablet to same volunteers yielded an average peak plasma level of 1.8 μg/ml. When TMS-19-Q·GC tablet (600mg) was given to four patients with chronic respiratory tract infections, the peak sputum level was 0. 38 μg/ml and the urinary excretion rate was about 3% on average. 3) Clinical evaluation and adverse reaction Twenty-nine patients with respiratory tract infections were treated with TMS-19-Q·GC tablet at daily dose of 600mg for 4 to 19 days. In clinical response of 29 patients, excellent was 10, good was 15, fair was 2, poor was 2. Over all efficacy rate was 86. 2%. Neither side effects nor changes in laboratory data attributable to the drug were observed in these patients.

Original language	English
Pages (from-to)	346-357
Number of pages	12
Journal	Chemotherapy
Volume	32
DOIs	https://doi.org/10.11250/chemotherapy1953.32.Supplement6_346
Publication status	Published - 1984 Jan
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.32.Supplement6_346

Cite this

Komori, M., Nakazato, H., Nagasawa, M., Koga, H., Watanabe, K., Fukuda, Y., Tomita, H., Ito, N., Sawatari, K., Shigeno, Y., Suzuyama, Y., Izumikawa, K., Saito, A., Hara, K., Sugawara, K., Mochida, C., Kaku, M., Yamaguchi, K., Iwasaki, H., ... Ohmagari, H. (1984). Laboratory and clinical studies on TMS-19-Q. Chemotherapy, 32, 346-357. https://doi.org/10.11250/chemotherapy1953.32.Supplement6_346

Laboratory and clinical studies on TMS-19-Q. / Komori, Munetaka; Nakazato, Hlroko; Nagasawa, Masao; Koga, Hlronobu; Watanabe, Koichi; Fukuda, Yoshiaki; Tomita, Hiroshi; Ito, Naomi; Sawatari, Katsuhiko; Shigeno, Yoshiteru; Suzuyama, Yoji; Izumikawa, Kinichi; Saito, Atsushi; Hara, Kohei; Sugawara, Kazuyuki; Mochida, Chikako; Kaku, Mitsuo; Yamaguchi, Keizo; Iwasaki, Hiromaru; Tsutsumi, Tsuneo; Ikebe, Akira; Nakano, Masamoto; Okuno, Kazuhiro; Oka, Rokushi; Koteda, Tsunetoshi; Ishizaki, Takashi; Oye, Toshiyuki; Sai, Masao; Ohmagari, Haruji.

In: Chemotherapy, Vol. 32, 01.1984, p. 346-357.

Research output: Contribution to journal › Article › peer-review

Komori, M, Nakazato, H, Nagasawa, M, Koga, H, Watanabe, K, Fukuda, Y, Tomita, H, Ito, N, Sawatari, K, Shigeno, Y, Suzuyama, Y, Izumikawa, K, Saito, A, Hara, K, Sugawara, K, Mochida, C, Kaku, M, Yamaguchi, K, Iwasaki, H, Tsutsumi, T, Ikebe, A, Nakano, M, Okuno, K, Oka, R, Koteda, T, Ishizaki, T, Oye, T, Sai, M & Ohmagari, H 1984, 'Laboratory and clinical studies on TMS-19-Q', Chemotherapy, vol. 32, pp. 346-357. https://doi.org/10.11250/chemotherapy1953.32.Supplement6_346

Komori, Munetaka ; Nakazato, Hlroko ; Nagasawa, Masao ; Koga, Hlronobu ; Watanabe, Koichi ; Fukuda, Yoshiaki ; Tomita, Hiroshi ; Ito, Naomi ; Sawatari, Katsuhiko ; Shigeno, Yoshiteru ; Suzuyama, Yoji ; Izumikawa, Kinichi ; Saito, Atsushi ; Hara, Kohei ; Sugawara, Kazuyuki ; Mochida, Chikako ; Kaku, Mitsuo ; Yamaguchi, Keizo ; Iwasaki, Hiromaru ; Tsutsumi, Tsuneo ; Ikebe, Akira ; Nakano, Masamoto ; Okuno, Kazuhiro ; Oka, Rokushi ; Koteda, Tsunetoshi ; Ishizaki, Takashi ; Oye, Toshiyuki ; Sai, Masao ; Ohmagari, Haruji. / Laboratory and clinical studies on TMS-19-Q. In: Chemotherapy. 1984 ; Vol. 32. pp. 346-357.

@article{0db8d0794cc14d6d885eb3e8badbd692,

title = "Laboratory and clinical studies on TMS-19-Q",

abstract = "Laboratory and clinical studies on TMS-19-Q, a new macrolide antibiotic, were carried out and the results were as follows 1) Antimicrobial activity The minimal inhibitory concentrations (MICs) of TMS-19-Q against 50 clinical isolates of Mycoplasma pneumoniae (M. pneumoniae) ranged from 0.0035 to 0. 06 μg/ml. The peak MIC of TMS-19-Q was 0. 015 μg/ml, which was superior to those of josamycin (JM) and oleandomycin (OL). The growth inhibitory effect of TMS-19-Q against M. pneumoniae in test tube revealed bactericidal activity in the concentration of 0.5 and 1.0 μg/ml. In the treatment of hamster experimentally infected with M. pneumoniae the viable organisms in the lungs decreased to 102cells/ml on the 3rd day. On the 10 th day of drug treatment, 80% (8 out of 10) of the hamsters receiving TMS-19-Q showed no viable M. pneumoniae cells upon the culture of their lungs. The antimicrobial activity of TMS-19-Q against 50 strains of Legionella pneumophila was almost same as that of erythromycin (EM). The MICs of TMS-19-Q against 155 clinical isolates (Streptococcus pneumoniae 47, Streptococcus pyogenes 54, Streptococcus faecalis 27 and Staphylococcus epidermidis 27) were compared with those of JM and EM. The antibacterial activity of TMS-19-Q was superior to that of JM and was almost equal to that of EM. 2) Absorption and excretion in humans The average peak plasma level of TMS-19-Q in six healthy adult volunteers after single oral dosage of 600 mg with TMS-19-Q·O tablet was 0. 5 μg/ml; while same dosage of TMS-19-Q with GC tablet to same volunteers yielded an average peak plasma level of 1.8 μg/ml. When TMS-19-Q·GC tablet (600mg) was given to four patients with chronic respiratory tract infections, the peak sputum level was 0. 38 μg/ml and the urinary excretion rate was about 3% on average. 3) Clinical evaluation and adverse reaction Twenty-nine patients with respiratory tract infections were treated with TMS-19-Q·GC tablet at daily dose of 600mg for 4 to 19 days. In clinical response of 29 patients, excellent was 10, good was 15, fair was 2, poor was 2. Over all efficacy rate was 86. 2%. Neither side effects nor changes in laboratory data attributable to the drug were observed in these patients.",

author = "Munetaka Komori and Hlroko Nakazato and Masao Nagasawa and Hlronobu Koga and Koichi Watanabe and Yoshiaki Fukuda and Hiroshi Tomita and Naomi Ito and Katsuhiko Sawatari and Yoshiteru Shigeno and Yoji Suzuyama and Kinichi Izumikawa and Atsushi Saito and Kohei Hara and Kazuyuki Sugawara and Chikako Mochida and Mitsuo Kaku and Keizo Yamaguchi and Hiromaru Iwasaki and Tsuneo Tsutsumi and Akira Ikebe and Masamoto Nakano and Kazuhiro Okuno and Rokushi Oka and Tsunetoshi Koteda and Takashi Ishizaki and Toshiyuki Oye and Masao Sai and Haruji Ohmagari",

year = "1984",

month = jan,

doi = "10.11250/chemotherapy1953.32.Supplement6_346",

language = "English",

volume = "32",

pages = "346--357",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Laboratory and clinical studies on TMS-19-Q

AU - Komori, Munetaka

AU - Nakazato, Hlroko

AU - Nagasawa, Masao

AU - Koga, Hlronobu

AU - Watanabe, Koichi

AU - Fukuda, Yoshiaki

AU - Tomita, Hiroshi

AU - Ito, Naomi

AU - Sawatari, Katsuhiko

AU - Shigeno, Yoshiteru

AU - Suzuyama, Yoji

AU - Izumikawa, Kinichi

AU - Saito, Atsushi

AU - Hara, Kohei

AU - Sugawara, Kazuyuki

AU - Mochida, Chikako

AU - Kaku, Mitsuo

AU - Yamaguchi, Keizo

AU - Iwasaki, Hiromaru

AU - Tsutsumi, Tsuneo

AU - Ikebe, Akira

AU - Nakano, Masamoto

AU - Okuno, Kazuhiro

AU - Oka, Rokushi

AU - Koteda, Tsunetoshi

AU - Ishizaki, Takashi

AU - Oye, Toshiyuki

AU - Sai, Masao

AU - Ohmagari, Haruji

PY - 1984/1

Y1 - 1984/1

N2 - Laboratory and clinical studies on TMS-19-Q, a new macrolide antibiotic, were carried out and the results were as follows 1) Antimicrobial activity The minimal inhibitory concentrations (MICs) of TMS-19-Q against 50 clinical isolates of Mycoplasma pneumoniae (M. pneumoniae) ranged from 0.0035 to 0. 06 μg/ml. The peak MIC of TMS-19-Q was 0. 015 μg/ml, which was superior to those of josamycin (JM) and oleandomycin (OL). The growth inhibitory effect of TMS-19-Q against M. pneumoniae in test tube revealed bactericidal activity in the concentration of 0.5 and 1.0 μg/ml. In the treatment of hamster experimentally infected with M. pneumoniae the viable organisms in the lungs decreased to 102cells/ml on the 3rd day. On the 10 th day of drug treatment, 80% (8 out of 10) of the hamsters receiving TMS-19-Q showed no viable M. pneumoniae cells upon the culture of their lungs. The antimicrobial activity of TMS-19-Q against 50 strains of Legionella pneumophila was almost same as that of erythromycin (EM). The MICs of TMS-19-Q against 155 clinical isolates (Streptococcus pneumoniae 47, Streptococcus pyogenes 54, Streptococcus faecalis 27 and Staphylococcus epidermidis 27) were compared with those of JM and EM. The antibacterial activity of TMS-19-Q was superior to that of JM and was almost equal to that of EM. 2) Absorption and excretion in humans The average peak plasma level of TMS-19-Q in six healthy adult volunteers after single oral dosage of 600 mg with TMS-19-Q·O tablet was 0. 5 μg/ml; while same dosage of TMS-19-Q with GC tablet to same volunteers yielded an average peak plasma level of 1.8 μg/ml. When TMS-19-Q·GC tablet (600mg) was given to four patients with chronic respiratory tract infections, the peak sputum level was 0. 38 μg/ml and the urinary excretion rate was about 3% on average. 3) Clinical evaluation and adverse reaction Twenty-nine patients with respiratory tract infections were treated with TMS-19-Q·GC tablet at daily dose of 600mg for 4 to 19 days. In clinical response of 29 patients, excellent was 10, good was 15, fair was 2, poor was 2. Over all efficacy rate was 86. 2%. Neither side effects nor changes in laboratory data attributable to the drug were observed in these patients.

AB - Laboratory and clinical studies on TMS-19-Q, a new macrolide antibiotic, were carried out and the results were as follows 1) Antimicrobial activity The minimal inhibitory concentrations (MICs) of TMS-19-Q against 50 clinical isolates of Mycoplasma pneumoniae (M. pneumoniae) ranged from 0.0035 to 0. 06 μg/ml. The peak MIC of TMS-19-Q was 0. 015 μg/ml, which was superior to those of josamycin (JM) and oleandomycin (OL). The growth inhibitory effect of TMS-19-Q against M. pneumoniae in test tube revealed bactericidal activity in the concentration of 0.5 and 1.0 μg/ml. In the treatment of hamster experimentally infected with M. pneumoniae the viable organisms in the lungs decreased to 102cells/ml on the 3rd day. On the 10 th day of drug treatment, 80% (8 out of 10) of the hamsters receiving TMS-19-Q showed no viable M. pneumoniae cells upon the culture of their lungs. The antimicrobial activity of TMS-19-Q against 50 strains of Legionella pneumophila was almost same as that of erythromycin (EM). The MICs of TMS-19-Q against 155 clinical isolates (Streptococcus pneumoniae 47, Streptococcus pyogenes 54, Streptococcus faecalis 27 and Staphylococcus epidermidis 27) were compared with those of JM and EM. The antibacterial activity of TMS-19-Q was superior to that of JM and was almost equal to that of EM. 2) Absorption and excretion in humans The average peak plasma level of TMS-19-Q in six healthy adult volunteers after single oral dosage of 600 mg with TMS-19-Q·O tablet was 0. 5 μg/ml; while same dosage of TMS-19-Q with GC tablet to same volunteers yielded an average peak plasma level of 1.8 μg/ml. When TMS-19-Q·GC tablet (600mg) was given to four patients with chronic respiratory tract infections, the peak sputum level was 0. 38 μg/ml and the urinary excretion rate was about 3% on average. 3) Clinical evaluation and adverse reaction Twenty-nine patients with respiratory tract infections were treated with TMS-19-Q·GC tablet at daily dose of 600mg for 4 to 19 days. In clinical response of 29 patients, excellent was 10, good was 15, fair was 2, poor was 2. Over all efficacy rate was 86. 2%. Neither side effects nor changes in laboratory data attributable to the drug were observed in these patients.

UR - http://www.scopus.com/inward/record.url?scp=0021144983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021144983&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.32.Supplement6_346

DO - 10.11250/chemotherapy1953.32.Supplement6_346

M3 - Article

AN - SCOPUS:0021144983

VL - 32

SP - 346

EP - 357

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -

Laboratory and clinical studies on TMS-19-Q

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this